Form 4: BioMarin Director Enyedy Reports Acquisition of 6,650 Shares of Common Stock

Director Mark J Enyedy reports acquiring 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.

Summary

• Mark J Enyedy, a director of BioMarin Pharmaceutical Inc., filed a Form 4 on May 22, 2025.
• The report details a transaction on May 20, 2025, where Enyedy acquired 6,650 shares of common stock.
• These shares were acquired through the granting of restricted stock units at a price of $0.
• Following the transaction, Enyedy directly owns 13,550 shares of BioMarin common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares by a director is mildly positive, suggesting confidence, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's increased stake in the company, which is generally viewed positively by investors.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive sign.

Key Dates

Keywords

Form 4, BioMarin, Enyedy, Director, Stock Acquisition, Restricted Stock Units, BMRN